Impact of COVID-19 on Lung Transplant Activity in Germany—A Cross-Sectional Survey

Abstract

The current COVID-19 pandemia affects health care systems worldwide, however, to a variable extent depending on the caseload in each country. We aimed to provide a cross-sectional overview of current limitations or adaptions in lung transplant programs in Germany in from January to May 2020 due to the COVID-19 pandemia caused by severe acute respiratory syndrome coronavirus 2. A cross-sectional survey assessing various aspects of lung transplant activity was sent to all active lung transplant programs (n = 12) in Germany. Eight centers (66%) responded to the survey within the requested time frame. Four centers (50%) reported their activity is not restricted at all and four centers (50%) reported on moderate general limitations. The overall lung transplant activity in Germany from January to May 2020 contains 128 bilateral and 11 single lung transplantations, which is similar to the same period in the year 2019 (126 bilateral transplantations and 12 single lung transplantations). The results suggest that the influence of the COVID-19 pandemia on lung transplantation activity in Germany has been moderate so far. Nevertheless, adaptions such as extensive testing of donors and recipients were introduced to reduce the likelihood of infections and increase patient safety. Alertness to changes in COVID-19 reproduction rates might be required until effective antiviral therapy or vaccination is available.

Keywords

transplantation - lung - infection - intensive care

Publication History

Received: 19 May 2020

Accepted: 15 June 2020

Article published online:
08 September 2020

• References

• 1 Organisation for Economic Co-operation and Development. Accessed 9/6/2020 at www.oecs.org/health
• 2 German Interdisciplinary Association for Intensive Care and Emergency Medicine, Intensive Care register. Accessed 9/6/2020 at https://www.intensivregister.de/#/index
• 3 Aigner C, Dittmer U, Kamler M, Collaud S, Taube C. COVID-19 in a lung transplant recipient. J Heart Lung Transplant 2020; 39 (06) 610-611
• 4 Kates OS, Fisher CE, Stankiewicz-Karita HC. et al. Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States. Am J Transplant 2020; 20 (07) 1885-1890
• 5 Zhu L, Xu X, Ma K. et al. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. Am J Transplant 2020;•••: Doi: 10.1111/ajt.15869
• 6 Li F, Cai J, Dong N. First cases of COVID-19 in heart transplantation from China. Am J Transplant 2020; Jul 20 (07) 1859-1863
• 7 Akalin E, Azzi Y, Bartash R. et al. COVID-19 and kidney transplantation. N Engl J Med 2020; 382 (25) 2475-2477
• 8 Carbajo-Lozoya J, Müller MA, Kallies S, Thiel V, Drosten C, von Brunn A. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. Virus Res 2012; 165 (01) 112-117
• 9 Angelico R, Trapani S, Manzia TM, Lombardini L, Tisone G, Cardillo M. The COVID-19 outbreak in Italy: initial implications for organ transplantation programs. Am J Transplant 2020; 20 (07) 1780-1784
• 10 de Vries APJ, Alwayn IPJ, Hoek RAS. et al. Immediate impact of COVID-19 on transplant activity in the Netherlands. Transpl Immunol 2020; 61: 101304